

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1430 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	mnam		
AITEICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/637,512	08/11/2000	Stanley M. Goldin	42,982 C3-CPA-C	1159
21874 759				· .
EDWARDS & P.O. BOX 9169	ANGELL, LLP		EXAMI	NER
BOSTON, MA 02209			O SULLIVAN, PETER G	
			ART UNIT	PAPER NUMBER
			1621	1777
			DATE MAILED: 06/17/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.

Applicant(s)

09/637,512

Goldin et al.

Examiner

Office Action Summary

Peter O'Sullivan

Art Unit 1621



	The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply·						
THE	IORTENED STATUTORY PERIOD FOR REPLY IS SE MAILING DATE OF THIS COMMUNICATION.					
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.						
- Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within period for reply is specified above, the maximum statutory period will apply to reply within the set or extended period for reply will, by statute, cause pply received by the Office later than three months after the mailing date of patent term adjustment. See 37 CFR 1.704(b).	y and will expire SIX (6) MONTHS from the mailing date of this communication.				
Status		•				
1) 💢	Responsive to communication(s) filed on Mar 31,	2003				
2a) 💢	This action is FINAL . 2b) ☐ This action	ction is non-final.				
3) 🗆	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
	tion of Claims					
4) 💢	Claim(s) <u>25-31</u>	is/are pending in the application.				
4	a) Of the above, claim(s) 28	is/are withdrawn from consideration.				
5) 🗌	Claim(s)	is/are allowed.				
6) 💢	Claim(s) <u>25-27 and 29-31</u>	is/are rejected.				
7) 🗆	Claim(s)	is/are objected to.				
8) 🗌	Claims	are subject to restriction and/or election requirement.				
Applicat	tion Papers					
9) \square The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the o	drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11) 🗆	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.				
	If approved, corrected drawings are required in reply	to this Office action.				
	12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120						
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
	All b)☐ Some* c)☐ None of:	i				
	. Certified copies of the priority documents hav					
	. Certified copies of the priority documents hav	ve been received in Application No				
	∴ ☐ Copies of the certified copies of the priority deapplication from the International Bure.	ocuments have been received in this National Stage				
4.41	e the attached detailed Office action for a list of the	e certified copies not received.				
	4)					
	a) Light The translation of the foreign language provisional application has been received.					
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)						
	e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)						
		or Donal.				

Art Unit: 1621

- Claims 25-31 are pending in this application which should be reviewed for errors.
 Applicants are requested to send copies of the references listed in their information disclosure statement with their next response. Claim 28 is held withdrawn from consideration as embracing non-elected subject matter.
- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 25-27 and 29-31 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Douglas et al. '077 for the reasons of record. Applicants' arguments have been given due consideration but are found non-persuasive. Douglas et al. disclose 1-cyclopropylmethyl-1-(2,6-dichlorophenyl) guanidine which is close to applicants' compounds. That Douglas et al.

Application/Control Number: 09/637,512

Page 3

Art Unit: 1621

generically disclose N,N-disubstituted compounds and then exemplify one shows they clearly contemplated these compounds as part of their invention.

- 4. Claims 25-27 and 29-31 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Weber et al. '976, taken with Durant et al., '675, and Durant et al., '604 for the reasons of record. Applicants' arguments have been given due consideration, but are found non-persuasive. Durant et al., '675, and Durant et al., '604, are relied on to teach that one nitrogen may have two substitutents and the others none or there may be N,N' disubstitution in similar compounds useful in the treatment of stroke, neurodegenerative diseases, etc.
- 5. No claim is allowed.
- 6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 09/637,512

Art Unit: 1621

Any inquiry concerning this communication should be directed to Peter O'Sullivan at 7. telephone number (703) 308-4526.

PRIMARY EXAMINER GROUP 1200

Page 4